Key result
Ivabradine lowers heart rate to reduce symptoms and hospitalizations in chronic stable angina and HFrEF.
Why the study?
This review summarizes the pharmacology, therapeutic use, and clinical evidence of ivabradine in cardiovascular disease.
Does ivabradine improve symptoms and reduce hospitalizations in patients with chronic stable angina and heart failure with reduced ejection fraction (HFrEF)?
Does ivabradine improve symptoms and reduce hospitalizations in patients with chronic stable angina and heart failure with reduced ejection fraction (HFrEF)?
Ivabradine is an effective and safe heart rate-reducing agent for the management of chronic stable angina and HFrEF.
Does not warrant practice change in stable angina or HFrEF; leaves open confirmation by randomized trials.
Ivabradine is a selective heart rate-reducing agent that inhibits the I(f) current in the sinoatrial node. This review summarizes the pharmacology, therapeutic use, and clinical evidence of ivabradine in cardiovascular disease. Ivabradine has been shown to reduce heart rate without affecting myocardial contractility or blood pressure, making it a valuable treatment option for patients with chronic stable angina and heart failure with reduced ejection fraction (HFrEF). Clinical trials have demonstrated the efficacy and safety of ivabradine in reducing angina symptoms, improving exercise tolerance, and decreasing hospitalizations for worsening heart failure. While ivabradine has a favorable safety profile, common side effects include visual disturbances, bradycardia, and atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Nabi et al. (2025) conducted a review in Cardiovascular disease. Ivabradine was evaluated. Ivabradine reduces heart rate and is an effective treatment for reducing angina symptoms, improving exercise tolerance, and decreasing hospitalizations in chronic stable angina and HFrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: